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SUMMARY 
Leishmania spp are protozoan parasites of the Trypanosomatidae family that 
cause disease in humans and animals. In general, infections with these parasites 
can be divided into three main forms namely, cutaneous, mucocutaneous, and 
visceral leishmaniases. The disease is prevalent in many tropical and subtropical 
regions of the world, where it is transmitted via the bite of an infected sand fly. 
Leishmaniasis has been known to be endemic in parts of Kenya from as far back 
as early in the 20th century. These endemic areas include Turkana, Baringo, 
Kitui, Machakos, Meru, West Pokot and Elgeyo Marakwet districts which have 
been reported to be endemic for kala-azar. Recent outbreaks of VL have been 
reported in the previously non-endemic districts of Wajir and Mandera in North 
Eastern Kenya between May 2000 and August 2001. The vector for VL in Kenya 
is Phlebotomus martini though other vectors including P. orientalis have been 
reported. Baringo district is the only foci reported where both VL and CL are 
known to occur in Kenya. The aetiological agents for CL which include L. majo
r which has been reported in Baringo; L. tropica in Laikipia, Samburu, Isiolo, 
Nakuru and Nyandarua districts while L. aethiopica has been reported in the Mt  
Elgon area. In Kenya, P. duboscqi, P. guggisbergi have been shown to be the 
vectors of L. major and L. tropica, respectively, while P. pediffer, P. longipes and 
P. elgonensis have been implicated as vectors of L. aethiopica. Since 1980, the 
Kenya Medical Research Institute (KEMRI) has spearheaded research on 
leishmaniases research in Kenya focusing on various aspects including 
characterization of Leishmania species, biology, and ecology of sand fly vectors, 
development of biological strategies for sand fly control, identification of animal 
reservoirs, diagnosis, new treatment strategies, new chemotherapeutic agents, 
and vaccine-related studies. KEMRI, a founding partner of the Drugs for 
Neglected Disease Initiative (DNDi), whose overall aim is to address lack of new 
or improved drugs for neglected diseases (which include leishmaniases, malaria, 
trypanosomiasis and chagas disease) has made major contributions in 
leishmaniases research and control in Kenya and the eastern Africa region.  
 
[Afr J Health Sci. 2006; 13: 7-21] 
 
Introduction 
Leishmania spp are protozoan parasites of the 
Trypanosomatidae family that cause disease in 
humans and animals. In general, infections 
with these parasites can be divided into three 
main forms namely, cutaneous (CL), 
mucocutaneous (MCL) and visceral (VL) (or 
kala azar) leishmaniasis [1]. The disease is 
prevalent in many tropical and subtropical 
regions of the world, where it is transmitted 
via the bite of an infected sand fly. Although  
leishmaniasis is endemic in 88 countries, 90% 
of CL cases have been reported in Afghanistan 
 
 
Syria, Saudi Arabia, Brazil, and Peru. VL, also 
known as kala azar, is the most dangerous 
form of the disease and occurs in Bangladesh, 
Brazil, India, and Sudan. A new syndrome in 
which Leishmania co-infects patients with 
AIDS is particularly deadly and has been 
reported in 33 countries including Kenya [1, 
2]. The impact of leishmaniasis on humans is 
enormous. One tenth of the world’s population 
is at risk and 2 million new cases are reported 
each year [1]. There are 22 species that cause 
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parasite species are associated with specific 
types of syndrome (see Table 1). For example, 
VL is caused by L. donovani and L. chagasi 
[4] whereas CL is caused by different species 
in different areas of the world. For example, L. 
major causes CL in the Middle East and L. 
mexicana causes CL in Central America. In 
addition, lesions caused by L. braziliensis 
complex in the skin can spread to the mucous 
membranes resulting in a late complication 
known as MCL, or espundia [5]. 
 
Table 1: Spectrum of leishmaniases, aetiological agents and worldwide distribution 






China, India, Iran, Sudan, Kenya, 
Ethiopía, Mediterranean basin, Brazil, 
Colombia, Venezuela, Argentina 
 




Mediterranean basin, Afghanistan, 
Middle East, W. and N. Africa, Kenya, 














Epidemiology of leishmaniases in Kenya 
Leishmaniasis has been known to be endemic 
in parts of Kenya from as far back as early in 
the 20th century [6]. An outbreak of VL in the 
King’s African Rifles troops encamped north 
of Lake Turkana in southwest Ethiopia was 
reported in the 1940s [7].  Since then Turkana, 
Baringo, Kitui, Machakos, Meru, West Pokot 
and Elgeyo Marakwet districts have been 
considered to be endemic for kala-azar. 
Between 1950 and 1960 more than 1,052 cases 
of VL were reported from these districts alone 
[6].   
A serious outbreak of VL was reported in 
Kitui district that began in 1952 with 303 
cases being reported and peaked in 1953 with 
2,142 cases. In the same year 157 cases were 
reported in the neighbouring Meru district [6].  
Another outbreak of VL in Meru district was 
reported in 1966 with 1,500 cases [8]. 
Phlebotomus martini Parrot, 1936 was shown 
to be the vector of kala-azar during that 
epidemic [9, 10]. Further outbreaks of VL 
were reported in Machakos district in the 
1970s, and again in Kitui district in the 1980s 
[11-13]. Baringo and the neighbouring 
districts such as West Pokot were first 
identified as leishmaniases foci in 1955 [14]. 
Since then, L. donovani transmitted by P. 
martini and L. major transmitted by P. 
duboscqi Neveu Lemaire, 1906 have been 
shown to exist in the region allopatrically, 
with rodents being the reservoir of CL (15-21). 
Other possible vectors that have been reported 
include P. celiae Minter, 1962, P. 
vansomeranae Heich, Guggisberg et Teesdale, 
1956 and Sergentomyia garnhami [22] for VL 
[23, 24]. VL caused by L. donovani, is 
endemic in Baringo District, Kenya. The 
disease occurring in Baringo has a focal 
distribution in the dry, hot areas below 1500 
metres and the infections may be characterized 
as follows: 1) asymptomatic 2) subclinical and 
self-limiting (not medically identifiable), and 
3) clinically manifest disease (that is medically 
identifiable). Half of the reported VL patients 
are between 5 and 14 years of age and 66% of 
them are males. A human case of a mixed L. 
donovani and L. major infection has been 
reported in this dual focus of VL and CL [25]. 
Often associated with sporadic incidents of the 
disease rather than epidemics, as many as 305 
cases of VL were reported in Baringo district 
alone in 1999 [26-29]. In the early 1990s, 3 
Maasai children were diagnosed with VL 
acquired locally in Kajiado district in the Rift 
Valley of Kenya.  L. donovani s.l. was isolated 
but a survey of other school children in the 
district did not reveal any more cases.  
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while P. orientalis Parrot, 1936 another vector 
for VL though present was rare and therefore 
transmission was attributed to P. martini [30]. 
More recently, an outbreak of VL was reported 
in the previously non-endemic Wajir and 
Mandera districts of North Eastern Kenya 
where during a period from May 2000 to 
August 2001, 904 patients were diagnosed 
with VL, with the patients coming from an 
area that spanned Wajir and Mandera districts, 
southern Somalia and southeast Ethiopia. 
Unusual rainfall patterns, malnutrition and 
migration of a Leishmania-infected population 
seeking food and security are thought to have 
contributed to this outbreak [31].  
Diffuse cutaneous leishmaniasis (DCL) 
was first described in Kenya in 1969 with 3 
patients from the indigenous communities in 
Bungoma district, around the Mt. Elgon area 
diagnosed [32]. L. aethiopica has since been 
identified as the aetiological agent, rodents as 
the animal reservoirs and P. pedifer Lewis, 
Mutinga et Ashford, 1972 to be the vector of 
DCL in the Mt. Elgon region [14, 33, 34]. 
Cutaneous leishmaniasis caused by L. 
major, and transmitted by P. duboscqi was 
first reported in Kitui district in the 1990s [35]. 
L. major has also been isolated from an 
infected monkey (Cercopithecus aethiops) 
from Kiambu District, central Kenya [36].  
However, no human cases have been reported 
from the district so far. 
      Meanwhile, active case detection and 
investigations of sand fly resting places 
conducted in the early 1990s, led to the 
identification of L. tropica CL in Central and 
Rift Valley provinces, mainly Laikipia, 
Samburu, Isiolo, Nakuru and Nyandarua 
districts [34].  Three sand fly species 
belonging to the subgenus Larroussius 
namely, P. pedifer, P. aculeatus Lewis, Minter 
et Ashford, 1974, P. guggisbergi Kirk et 
Lewis, 1952 and one Paraphlebotomus species 
(P. saevus Parrot et Martin, 1932) were found 
to be common in these areas [34,37-39]. P. 
guggisbergi has since been shown to be the 
vector for L. tropica in Kenya [40].   
 
Contributions of the Kenya Medical 
Research Institute (KEMRI) to 
leishmaniases research and control in 
Kenya 
Currently, disease control strategies rely on 
chemotherapy to alleviate the disease, on 
vector suppression, and personal protection to 
reduce transmission [1]. To date, there are no 
proven vaccines against any form of 
leishmaniasis [41]. Since 1980, the Kenya 
Medical Research Institute (KEMRI) has made 
major contributions to leishmaniases research 
and control focusing on various aspects 
including characterization of Leishmania 
species, biology, and ecology of sand fly 
vectors, development of biological strategies 
for sand fly control, identification of animal 
reservoirs, diagnosis, new treatment strategies, 
new chemotherapeutic agents, and vaccine-
related studies.  
         This has been achieved through 
collaborations with several agencies including 
the UN Development Program/World 
Bank/World Health Organization Special 
Program for Research and Training in Tropical 
Diseases (TDR), US Army Medical Research 
Unit-Kenya (USAMRU-K), the Ministry of 
Health’s Division of Vector Borne Diseases 
(DVBD), International Centre for Insect 
Physiology and Ecology (ICIPE), the Institute 
for Primate Research (IPR), Médecins Sans 
Frontières (MSF), local and international 
universities and colleges. As a result of this 
KEMRI scientists regularly participate in the 
Ministry of Health’s Disease Outbreak 
Management Unit, (DOMU), WHO and MSF 
to assist in the control of Kala azar outbreaks 
in Kenya and in the eastern African region. 
The Centre for Biotechnology Research and 
Development (CBRD) and the Centre for 
Clinical Research (CCR) of KEMRI have 
spearheaded leishmaniasis research. The 
Institute is a leader in sand fly biology 
research and it maintains the only sand fly 
colony in sub-Saharan Africa. The Centre for 
Clinical Research (CCR), designated a Good 
Clinical Practice (GCP) compliant facility, has 
also been involved in testing new anti-
leishmanial drugs. KEMRI has an animal care 
facility that supports laboratory research in 
leishmaniasis.  
       The following sections summarize 
research activities on leishmaniases in Kenya 
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Characterization of Leishmania species 
in Kenya 
It is essential to know the identity of the 
parasite(s) in each focus, since this knowledge 
has implications for control and treatment of 
leishmaniases [42]. Therefore, isolates 
originating either from research, 
entomological and zoological activities should 
be identified and compared with international 
references stains. Cryobanks are also required 
for storage and for future availability. To 
address this need, a laboratory at CBRD of 
KEMRI was designated a regional reference 
centre for leishmaniasis taxonomy in Kenya. 
This facility maintains a cryobank of 
Leishmania isolates and is internationally 
referred to as Nairobi Leishmania Bank 
(NLB). At least 1800 Leishmania and other 
Leishmania-like isolates obtained from 
humans, other vertebrates, sand fly vectors and 
other arthropods from Kenya and other parts 
of Africa have been cryopreserved in this 
bank.  
Through this bank it has been possible to 
compare the biological characteristics of the 
Leishmania parasites in Kenya and the 
neighbouring countries [43]. Zymodeme 
analysis of the Kenyan VL and CL isolates 
resulted in the identification of 11 
subpopulations of the L. donovani species 
complex and six subpopulations of the L. 
tropica species complex endemic to different 
geographic areas of Kenya [37, 39]. A 
Leishmania-like isolate from the reptiles has 
since been identified as Sauroleishmania 
(RGER/KE/89/NLB-1236) and has been 
shown experimentally to cause L. major-like 
cutaneous lesions and visceral leishmaniasis in 
BALB/c mice [44].  
 
Research on sand fly biology and control 
in Kenya 
Control of phlebotomine sand flies remains a 
difficult problem throughout the world 
because of the insects' very highly specialized 
breeding sites. Use of insecticides remains the 
most effective method of sand fly control. 
However, resistance to insecticides has proved 
to be a major challenge. Use of bed nets or 
permethrin impregnated wall cloth, repellents 
and other personal protective measures have 
proved to be unreliable in Kenya [45]. With 
these shortcomings, there is need to identify 
new insecticides. 
In general, control of leishmaniasis is 
hampered by the diversity of vectors, 
parasites, and reservoir hosts and the 
interventions must take into account these 
differences. It is therefore crucial to 
understand the biology of the leishmaniasis as 
well as that of the sand fly. The exploration of 
host-parasite interactions between species of 
Leishmania and respective vectors represents a 
wide and important field for basic and applied 
research as well. To address these needs, 
laboratory reared sand fly colonies have been 
established at KEMRI. These include P. 
martini and P. duboscqi Neveu-Lemaire 
(Diptera: Psychodidae) [17]. It is through 
studies done using P. duboscqi that L. major 
development within the sand fly was 
unravelled [46]. These studies have shown that 
it takes a period of 4-25 days, for the parasite 
to develop inside the sand fly and during the 
next blood meal the infective metacyclic stage 
enters the body of host through a sand fly bite 
[46, 47]. At least five developmental forms 
have also been recognized during development 
in the subgenus Leishmania, namely, procyclic 
promastigotes, nectomonad promastigotes, 
haptomonad promastigotes, paramastigotes, 
and metacyclic promastigotes [46]. 
Understanding of sand fly biology is also 
important in designing new control 
programmes in leishmaniases. It has also been 
shown that P. perniciosus can acquire and 
allow the development of L. infantum by 
feeding on L. infantum/HIV coinfected 
patients. Since this sand fly is an important 
vector of VL in southern Europe, a new 
natural anthroponotic cycle could be 
considered in the epidemiology of L. 
infantum/HIV coinfection [48]. This 
phenomenon is known as xenodiagnosis and 
this technique has been shown to be able to 
detect the presence of Leishmania parasites in 
a patient that other conventional diagnostic 
techniques failed (48). Therefore, the design of 
leishmaniasis control programs and the 
management of coinfected individuals should 
take these findings into account in southern 
Europe [48].  
Investigations on vectors of leishmaniases 
in Kenya started only in the early 1950’s when 
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major disease epidemic outbreak [49]. Since 
then these investigations on vectors have 
resulted in identification of the main vectors 
for both VL and CL. P. martini Parrot has 
been confirmed as the vector for L. donovani 
the aetiological agent of VL in Kenya, 
southern Sudan, and Ethiopia [15, 21,50]. This 
sand fly species rests and breeds in termite 
hills, animal burrows, tree holes, and house 
walls [51, 52]. It feeds mainly on goats, 
rabbits, and humans, and to a lesser extent on 
dogs, cattle, and other hosts [52]. Another 
vector for L. donovani in Kenya is P. 
orientalis which occurs in Kajiado district of 
Kenya [30].  
Among the cutaneous forms of 
leishmaniasis P. duboscqi Neveu-Lemaire 
(Diptera: Psychodidae) has been confirmed as 
the main vector of L. major in West Africa and 
the Rift Valley of Kenya [53, 54]. P. pediffer, 
P. longipes and P. elgonensis have been 
implicated as vectors of L. aethiopica 
occurring in the vicinity of Mount Elgon, 
Kenya [32, 34, 55, 56]. P. guggisbergi has 
been incriminated as a vector of L. tropica 
endemic in Samburu, Laikipia, Narok, Nakuru 
and Nyandarua districts of Kenya [37, 40].  
 
Research on animal reservoirs of 
Leishmania in Kenya 
Extensive research has been carried out in 
eastern Africa for animal reservoirs of both 
VL and CL. The domestic dog [54] has been 
the only domestic animal so far implicated as a 
possible reservoir for visceral leishmaniasis 
[58]. For cutaneous leishmaniasis caused by L. 
aethiopica, the rock (Denobrahyrax arboveus) 
and tree (Procavia johnstoni) hyraxes and the 
giant rat (Cricetomys sp) are the proven 
reservoirs of the disease [33], while several 
species of rodents have been demonstrated to 
harbor L. major which include Tatera robusta, 
Arvicanthis niloticus and Aethomys kaiseri 
[15, 18, 19]. The domestic sheep [58] and 
goats [59] which were initially suspected to be 
animal reservoirs for VL have since been 
proven experimentally to be non susceptible to 
L. donovani infection and therefore unlikely to 
be a synanthropic reservoir of this parasite [60, 
61] 
 In Kenya, anthroponotic VL in Baringo 
District has shown that Leishmania 
deoxyribonucleic acid (DNA) is detectable in 
patients 10.5 months before diagnosis, up to 3 
years after diagnosis and apparently successful 
treatment. Sub clinical cases have also been 
reported to have detectable circulating parasite 
DNA in their blood. These findings may 
indicate that sub clinical cases can be a 
reservoir and formerly treated VL patients can 
remain a reservoir for a long time. 
Xenodiagnosis may be important in such areas 
to determine whether sub clinical cases and 
former VL patients do have role in 
transmission of VL in Kenya [62].  
 
Research on new diagnostic tests for 
leishmaniases  
Sensitive, specific, reproducible, feasible and 
cheap diagnostic tests are needed if one wants 
to build an effective and efficient test-
treatment strategy [63]. Since Leishman 
identified the parasite in 1901, the definitive 
diagnosis of VL has relied on demonstrating 
the organism by microscopy in smear or 
culture of aspirates or tissue [64,65]. However, 
a splenic-aspiration technique [66] which is 
used to acquire these tissues can hardly be 
recommended for rural district hospitals 
because of the risk of fatal haemorrhage, 
which subsists even with the recently 
introduced safer procedures [67]. Therefore, 
the search for a suitable alternative for splenic 
aspirates is thus still going on.  
        Over the past 20 years, several 
serological tests have been developed showing 
high sensitivity for visceral disease [68]. 
Enzyme linked immunosorbent assays 
(ELISA) for detecting leishmanial antibodies 
has also been established and successfully 
applied in clinical routine and sero-
epidemiological surveys in Kenya [26, 27, 69]. 
Of all the available serological tests, the direct 
agglutination test (DAT) has proved to be the 
most appropriate one for field use in Kenya 
[29, 63, 70, 71].  
         Other methods that have been tested 
include isoenzyme analysis [72, 73]; kDNA 
based techniques [74, 75]. In recent years 
polymerase chain reaction (PCR) techniques 
for leishmaniases have been developed and 
applied to visceral disease with contradictory 
results [76, 77]. Apart from the fact that PCR 
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sampling, it is not exactly the type of 
appropriate technology needed in endemic 
areas.  
 
Research on new treatment strategies and 
chemotherapeutic agents for  
leishmaniases  
Neglected diseases such as leishmaniasis, 
trypanosomiasis, Chagas disease, and malaria 
have had a devastating impact on the world's 
poor. These treatable, infectious tropical 
diseases have been progressively marginalized 
by those in charge of making research 
programme decisions, both in the public and 
private sectors. Unfortunately, people 
suffering from these diseases do not constitute 
a market lucrative enough to attract investment 
in research and development for new drugs. 
KEMRI is a founding partner of an 
international effort, Drugs for Neglected 
Disease Initiative (DNDi), whose aim is to 
address lack of new or improved drugs for 
neglected diseases such as leishmaniasis. 
KEMRI’s Centre for Clinical Research (CCR) 
brings to DNDi a rich history of involvement 
in tropical diseases and expertise in clinical 
research for neglected diseases.  
Over the last 25 years, scientists at CCR 
have been addressing the issue of treatment 
options for Kala-azar. The treatment of 
leishmaniasis, as currently conducted in Kenya 
with sodium stibogluconate, is unsatisfactory 
as it is expensive, resistance and relapses may 
occur [78]. However, it is through 
collaborative efforts of CCR scientists several 
new drugs or including AmBisome® a safer 
and more effective lipid formulation of 
Amphotericin B (second line VL treatment); 
sitamaquine and aminosidine, alone or 
combined with sodium stibogluconate, in 
visceral leishmaniasis, compared to treatment 
by stibogluconate alone have been tested [79]. 
Worldwide, Leishmania parasites are 
increasingly becoming more and more 
resistant to antileishmanial drugs. The 
increment of in vitro antimony resistance due 
to intermittent drug exposure [80-83], the 
isolation of antimony-resistant Leishmania 
strains from patients with unresponsive CL 
[84,85], and recent reports, of numerous cases 
of VL among patients with the human 
immunodeficiency virus [86-89] indicate the 
need for new therapeutic agents for control 
and management of leishmaniases. Extensive 
studies of new drugs with antileishmanial 
activities, including natural products and 
synthetic compounds, have been undertaken 
worldwide [90], but problems associated with 
the currently available drugs remain 
unresolved. In recent years, there has been 
growing interest in alternative therapies and 
use of natural products, especially those 
derived from plants [91]. The use of plant-
based medicine for healing and prophylaxis is 
as ancient and universal as medicine itself. 
Recent research undertaken in KEMRI has led 
to discovery of plant-based products with 
antileishmanial activities. For instance, studies 
have shown that leaf, root and stem extracts 
from Ajuga remota and Trichilla emetica have 
antileishmanial activity when tested against L. 
donovani in vitro and in vivo [92]. Some of the 
active compounds isolated from plants include 
iridoid glucosides, limonoids and terpenoids 
[92]. KEMRI has also initiated studies aimed 
at testing extracts/compounds from medicinal 
plants used widely by the local people for 
treating splenomegaly related ailments in 
leishmaniasis endemic areas of Kenya [92]. A 
long term goal of this research is to develop 
oral drugs for leishmaniases. These drugs have 
an advantage of reducing treatment-related 
socioeconomic difficulties (inadequate health 
care infrastructure and the long period of 
patient hospitalization) prevalent in the 
endemic areas. 
          Among the products tested for 
antileishmanial activity in the rodent models 
(BALB/c mice and Syrian hamsters) at 
KEMRI includes metal ion chelators namely 
(Pristane, EGTA, and HEEDTA). Results of 
these studies suggests that metal ions chelators 
have antileishmanial potential in vivo against 
L. donovani but their activity was low 
compared to that of Pentostam [93, 94]. 
 
Vaccine related research for  
leishmaniases in Kenya 
Currently there is no vaccine available for use 
against any form of leishmaniases worldwide 
[41]. In brief, vaccines based on killed 
promastigotes with or without Mycobacterium 
bovis BCG have shown significant protection 
against L. braziliensis [95], L. mexicana or 
braziliensis, L. major [96] and L. donovani 
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models, several other vaccine preparations are 
being tested. Examples include: attenuated live 
parasites [98]; subunit vaccines delivered by 
live carriers such as BCG expressing the 
surface protease gp63 of L. major [99]; 
vaccinia virus expressing the glycoprotein 
gp46/M2/PSA-2 [100]; gp63 expressed in 
attenuated Salmonella typhimurium [101]; 
purified recombinant or native proteins 
formulated with an adjuvant such as the 
Leishmania-homologue of receptors for 
activated C kinase (LACK) plus IL-12 [103, 
102], gp46/M2/PSA-2 or protein dp 72 plus 
Corynebacterium parvum [104], T cell 
epitopes plus Poloxamer 407 [104]; and 
vaccination with DNA encoding gp63 [105], 
LACK [106], or gp46/M2/PSA-2 [107].  In 
general, these vaccination protocols elicited 
partial protection against L. major.   
Vaccine research at KEMRI is still at the 
rodent model stage of development in 
leishmaniases. So far live-attenuated L. major 
parasites [108], L. major culture-derived 
soluble exogenous antigens (SEAgs) [109], 
lipophosphoglycan (LPG) alone or LPG plus 
Mycobacterium bovis Bacille Calmette-Guerin 
(BCG) [110], and LPG plus salivary gland 
lysates [111] have been tested. 
Transmission blocking vaccine studies in 
leishmaniasis have also been undertaken at 
KEMRI. These studies have shown that LPG 
is an excellent candidate as a transmission 
blocking vaccine against L. major infections 
[112,113]. In these studies, sand flies, which 
fed on BALB/c mice, immunized with L. 
major-derived LPG [114] or monoclonal 
antibodies raised against LPG [115] showed 
that parasite development was inhibited at the 
log phase (procyclic) of the parasite. There 
was also a marked reduction in the numbers of 
metacyclic promastigotes developing, leading 
to reduced transmission of L. major to naive 
BALB/c mice [113]. It has also been shown 
that P. duboscqi gut lysates and proteins 
present in L. major-derived LPG share two 
common proteins of molecular weights 105 
kDa and 106 kDa [115]. The goal of these 
studies has been to develop a vaccine that can 
be utilized both to reduce transmissible 
infections within the sand fly and disease 
severity within the host. Some of the important 
findings relevant to vaccine research also 
include the determination of an inoculum dose 
required for effecting a visceral infection in 
rodents [116].  
         At the Institute for Primate Research 
(IPR) in Karen, Nairobi it has been shown that 
the vervet monkey (African Green monkey) is 
a good model for human cutaneous or visceral 
leishmaniases [117, 118]. Availability of a 
non-human primate model of leishmaniasis 
facilitates the study of different aspects of this 
disease and will accelerate the development of 
vaccines and new drugs for leishmaniases. 
Using this model the safety and 
immunopotency of the recombinant gp63 
mixed with Baccille Calmette Guerin (BCG) 
vaccines [119], and also the adjuvant potential 
of two doses of IL-12 when used with a killed 
L. major vaccine [120] have been evaluated. It 
has also been demonstrated that high cross-
reactivity between L. donovani and L. major, 
and that L. donovani protects against L. major 
infections [121]. These findings have 




Although various aspects of the transmission 
and control of leishmaniases have been studied 
in Kenya, the impact of visceral leishmaniasis 
or kala azar is still enormous in Kenya. 
Control measures against sand flies and 
reservoir hosts need to be further evaluated in 
terms of their effect on disease incidence. Very 
few attempts have also been made to quantify 
local factors or to identify the causative 
mechanisms of epidemics in previously 
nonendemic or low endemic areas. Research to 
develop more effective drugs that meet the 
current standards of safety also remains a high 
priority. It is hoped that the entry of Drugs for 
Neglected Disease Initiative (DNDi), whose 
aim is to address lack of new or improved 
drugs for neglected diseases including 
leishmaniases will mobilize inter-country, 
international support and collaboration in 
terms of both finance and technical expertise 
towards achieving this goal. Diagnostic and 
vaccine-related studies are also still required to 
be pursued vigorously. 
Many cases of leishmaniases still go 
unreported or undiagnosed hence the official 
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determining the actual number of cases in 
Kenya. Health education activities are still 
required to sensitize people living in endemic 
areas, medical and public health managers, and 
individuals at risk on leishmaniases. Decision 
makers should be sensitized on the importance 
of the leishmaniases as a public health 
problem so that they will support and defend 
control programmes. Notwithstanding these 
challenges, contributions from KEMRI and its 
partners towards leishmaniases control in 
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